Holen Sie sich die Stockscreener-App
1.16
3.57%
0.04
Schlusskurs vom Vortag:
$1.12
Offen:
$1.12
24-Stunden-Volumen:
78,746
Relative Volume:
0.23
Marktkapitalisierung:
$22.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.08M
KGV:
-0.3946
EPS:
-2.94
Netto-Cashflow:
$-25.68M
1W Leistung:
-1.74%
1M Leistung:
-9.38%
6M Leistung:
-28.83%
1J Leistung:
+70.59%
1-Tages-Spanne:
$1.08
$1.175
1-Wochen-Bereich:
$1.08
$1.25
52-Wochen-Spanne:
$0.603
$2.55
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
Firmenname
Chemomab Therapeutics Ltd Adr
Sektor
Branche
Telefon
972-77-331-0156
Adresse
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Vergleichen Sie CMMB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
1.16 | 22.26M | 0 | -33.08M | -25.68M | -2.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-13 | Eingeleitet | Maxim Group | Buy |
| 2024-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-12-19 | Fortgesetzt | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr Aktie (CMMB) Neueste Nachrichten
The Aurora Cannabis Inc (NASDAQ: ACB) Stock Price: Is It Overvalued? - Stocks Register
How Stable And Growing Is Globavend Holdings Ltd (NASDAQ: GVH)? - Stocks Register
Before Buying AYRO Inc (NASDAQ: AYRO) Stock, Read This First - Stocks Register
Is Advance Auto Parts Inc (NYSE: AAP) A Good Investment For New Investors Now? - stocksregister.com
Nu Holdings Ltd (NYSE: NU) Has Great Upside Potential - stocksregister.com
ZEEKR Intelligent Technology Holding Ltd. ADR (NYSE: ZK): Getting A Free Pass? - stocksregister.com
AT&T, Inc (NYSE: T) Jumps 1.59%: What Could Be On The Way Going Forward? - Stocks Register
Adma Biologics Inc (NASDAQ: ADMA): Blank Check For Growth? - Stocks Register
A Bullish 2025 Outlook For Blink Charging Co (NASDAQ: BLNK) Shares - Stocks Register
In 2025, Linkers Industries Ltd (NASDAQ: LNKS) Shares Will Likely Be Bullish - Stocks Register
Carrier Global Corp (NYSE: CARR): On Track To A Higher Share Price - Stocks Register
Before Buying Avantor Inc (NYSE: AVTR) Stock, Read This First - stocksregister.com
Ally Financial Inc (NYSE: ALLY): An Enticing Stock To Watch - stocksregister.com
Nebokitug shows promise in PSC treatment trial - Investing.com
Does DLocal Limited (NASDAQ: DLO) Still Need To Convince Analysts? - stocksregister.com
Think You Need A Good Stock? Look At This Scilex Holding Company (NASDAQ: SCLX) Analysis - stocksregister.com
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - stocksregister.com
Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat
How analysts predict Chemomab Therapeutics Ltd ADR (CMMB) will perform this quarter? - US Post News
Nebokitug positioned as potential first FDA-approved PSC treatment By Investing.com - Investing.com South Africa
LogicMark Inc (LGMK) Recovers 0.71% From Low: Are We There Yet? - Stocks Register
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewswire Inc.
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Investing.com
Chemomab reports progress in PSC treatment trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why - Zacks Investment Research
What You Need To Know About Chemomab Therapeutics Ltd.'s (NASDAQ:CMMB) Investor Composition - Yahoo Finance
CMMB News Today | Why did Chemomab Therapeutics stock go down today? - MarketBeat
Finanzdaten der Chemomab Therapeutics Ltd Adr-Aktie (CMMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):